Ernexa Therapeutics Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Ernexa Therapeutics Inc. stock issued during period, value, new issues for the quarter ending 2023-12-31 was $0.00.
- Ernexa Therapeutics Inc. stock issued during period, value, new issues for the quarter ending 2023-09-30 was $0.00.
- Ernexa Therapeutics Inc. stock issued during period, value, new issues for the quarter ending 2023-06-30 was $580.00K.
- Ernexa Therapeutics Inc. stock issued during period, value, new issues for the quarter ending 2018-06-30 was $1.38M.
- Ernexa Therapeutics Inc. stock issued during period, value, new issues for fiscal 2023 was $580.00K.
- Ernexa Therapeutics Inc. stock issued during period, value, new issues for fiscal 2018 was $1.38M, a 22.45% decline from fiscal 2017.
- Ernexa Therapeutics Inc. stock issued during period, value, new issues for fiscal 2017 was $1.77M, a 34.14% decline from fiscal 2016.
- Ernexa Therapeutics Inc. stock issued during period, value, new issues for fiscal 2016 was $2.69M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $580.00K 10-K · filed 2025-03-12 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | |
| 2023-06-30 | $580.00K 10-Q · filed 2024-08-13 | |
| 2018-12-31 | $1.38M 10-K · filed 2019-03-22 | |
| 2018-06-30 | $1.38M 10-Q · filed 2018-08-06 | |
| 2017-12-31 | $1.77M 10-K · filed 2019-03-22 | |
| 2016-12-31 | $2.69M 10-K · filed 2018-03-09 | |
| 2014-12-31 | $6.37M 10-K · filed 2016-03-15 | |
| 2013-12-31 | $2.34M 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |